Sacituzumab govitecan is in clinical development for the treatment of adult patients with
metastatic or locally advanced, unresectable urothelial cancer (UC). UC occurs on the lining of the
renal pelvis, ureter, bladder and urethra, and other parts of the urinary system. Locally advanced
bladder cancer indicates that the cancer has grown through the bladder wall or has spread into
lymph nodes, while metastatic UC occurs when the cancer has spread to other parts of the body.
Durable responses are rare with current standard of care treatments. Therefore, treatment
approaches with longer-term disease control and extending to broader metastatic UC patient
populations are needed.
Sacituzumab govitecan for urothelial cancer
Sacituzumab govitecan is in clinical development for the treatment of adult patients with metastatic or locally advanced, unresectable urothelial cancer (UC). UC occurs on the lining of the renal pelvis, ureter, bladder and urethra, and other parts of the urinary system. Locally advanced bladder cancer indicates that the cancer has grown through the bladder wall or has spread into lymph nodes, while metastatic UC occurs when the cancer has spread to other parts of the body.
Interventions:
Sacituzumab Govitecan (IMMU-132; Trodelvy)
Indications:
Urothelial cancer
Therapeutic Areas:
Urological Cancer
Year:
2022